基于骨肉不相亲理论探讨补肾健脾中药影响骨髓间充质干细胞治疗肌少–骨质疏松症  

Exploring the Influence of Kidney and Spleen Tonifying Herbs on BMSCs for Sarcopenia-Osteoporosis Based on the Theory of Incompatibility of Flesh and Blood

作　　者：游高冉 

机构地区：[1]成都中医药大学临床医学院,四川 成都

出　　处：《中医学》2025年第3期966-972,共7页Traditional Chinese Medicine

摘　　要：影响老年人的常见疾病肌少–骨质疏松症,大大增加了老年人跌倒、骨折、住院等情况的发生,加重社会经济和医疗负担。在社会人口老龄化加剧的情况下,人们逐渐开始重视肌少–骨质疏松症。肌少–骨质疏松症可供选择的药物较少,疗效存在不确定性。骨髓间充质干细胞(bone mesenchymal stem cells, BMSCs)作为最理想的组织工程研究的种子细胞,可向成骨细胞、成肌细胞分化,对治疗肌少–骨质疏松症有潜在的临床意义。中医药是中国传统文化瑰宝,研究表明中药及其有效成分可有效促进BMSCs增殖分化,本文从中医“骨肉不相亲”机理讨论肌少–骨质疏松症,研究补肾健脾中药对骨髓间充质干细胞的影响,期望为中药干预BMSCs治疗肌少–骨质疏松症提供新的方向和思路。A common disease affecting the elderly, sarcopenia-osteoporosis, greatly increases the incidence of falls, fractures, and hospitalization among the elderly, adding to the socioeconomic and medical burden. In the context of an aging society, attention is gradually being paid to sarcopenia-osteoporosis. There are fewer drugs available for sarcopenia-osteoporosis, and there is uncertainty about efficacy. Bone marrow mesenchymal stem cells (BMSC), as the most ideal seed cells for tissue engineering research, can differentiate into osteoblasts and myoblasts, and have potential clinical significance for the treatment of sarcopenia-osteoporosis. Traditional Chinese medicine is a treasure of Chinese traditional culture, and studies have shown that it and its active ingredients can effectively promote the proliferation and differentiation of BMSC. In this paper, we discussed sarcopenia-osteoporosis from the mechanism of the incompatibility of flesh and blood theory in traditional Chinese medicine, and investigated the effects of kidney-healthy and spleen-healthy conventional Chinese medicines on bone marrow MSCs, with the expectation of providing new directions and idea

关 键 词：肌少–骨质疏松症 骨肉不相亲 骨髓间充质干细胞 中药治疗 

分 类 号：R274[医药卫生—中医骨伤科学] R259[医药卫生—中医学]